Current trials | Chris O'Brien Lifehouse

Current Recruiting Clinical Trials

If you wish to participate in a clinical trial, speak with your treating oncologist or GP to see if there are current trials you may be suitable for.

If  you cannot find a suitable trial under your specific cancer type, please refer to “Solid Tumours and Phase 1 Studies” for trials including multiple cancer types.

There are currently no trials actively recruiting to this stream. Please refer to “Solid Tumours and Phase 1 Studies” for trials including multiple cancer types.

  • TRIAL REFERENCE:  LH16.037 PCR-MIB
    SUMMARY: Clinical Study No. [ANZUP 1502], Phase II study of Pembrolizumab with ChemoRadiotherapy as treatment for muscle invasive bladder cancer protocol
    LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.040 THOR
    SUMMARY: A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
  • LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.023 ACED
    SUMMARY: A Phase II randomised placebo-controlled, double blind, multisite study of Acetazplamide versuss placebo for management of cerebral oedema in recurrent and / or progressive High Grade Glioma requiring treatment with Dexamethasone (the ACED Trial)
    LEAD INVESTIGATOR: Dr Hao Wen-Sim
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.003 NUTMEG
    SUMMARY:  A Randomised Phase II Study of NivIUmab and TeMozolomide alone in newly diagnosed Elderly patients with Glioblastoma (NUTMEG)
    LEAD INVESTIGATOR: Prof John Simes
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.052 CO40016
    SUMMARY: A Double-Blind, Placebo-Controlled, Randomised Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With Pik3ca/Akt1/Pten-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor – Positive, Her2-Negative Breast Cancer
    LEAD INVESTIGATOR: A/Prof Jane Beith
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.029 WinPro
    SUMMARY: An open-label, randomized, window of opportunity study between diagnosis and definite surgery, to assess the effect of antiestrogen therapies, alone and in combination with microionized progesterone (prometrium) in patients with newly diagnosed ER+PR+ breast cancer.
  • LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.043 AB928-CSP0002
    SUMMARY: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies.
    LEAD INVESTIGATOR: Dr Chen Lee
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.011 CHARIOT  BCT -1702
    SUMMARY: A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab
    LEAD INVESTIGATOR: Dr Jane Beith
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.050 CANNABIS
    SUMMARY: CTC0146 : Pilot and definitive randomised double-blind, placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (The CannabisCINV study)
    LEAD INVESTIGATOR: Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH15.055 ASCOLT (AG0213CR)
    SUMMARY: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre Double Blind, Randomised Placebo Controlled Phase III Trial (ASCOLT Trial)
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.004 DYNAMIC
    SUMMARY: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II colon Cancer (DYNAMIC)
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.027 SPAR
    SUMMARY: A randomized, placebo-controlled phase II trial of Simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.040 THOR
    SUMMARY: A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations.
    LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.042 AB928-CSP0003
    SUMMARY: A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies.
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.002 FPA144
    SUMMARY: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1 (FIGHT)
    LEAD INVESTIGATOR: Dr Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.043 AB928-CSP0002
    SUMMARY: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies.
    LEAD INVESTIGATOR: Dr Chen Lee
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH14.021 ANZUP 1302
    SUMMARY:  Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk metastatic germ cell tumours (P3BEP Trial)
    LEAD INVESTIGATOR:  A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.021 TIGER
    SUMMARY:  A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
    LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH15.004 TROG 12.01 HPV OROPHARYNX
    SUMMARY: A Randomised Trial of Weekly Cetuximab And Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV OROPHARYNX)
    LEAD INVESTIGATOR: Dr Mo Mo Tin
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH15.052 BR.31
    SUMMARY: A phase III prospective double blind placebo controlled randomized study of adjuvant MED14736 in completely recsected non-small cell lung cancer
    LEAD INVESTIGATOR: Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.019 EnRICH
    SUMMARY: Embedding Research (and Evidence) in Cancer Healthcare (EnRICH)
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.046 OSCILLATE
    SUMMARY: A Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer
    LEAD INVESTIGATOR: Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.058 AMG 757
    SUMMARY: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer’ 20160323
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.060 MK3475-598
    SUMMARY: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.024 MK3475-789
    SUMMARY: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
    LEAD INVESTIGATOR: Prof Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.025 BO40336 (ALINA)
    SUMMARY: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
    LEAD INVESTIGATOR: Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.017 61186372EDI1001
    SUMMARY: A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMET Anitbody, in Subjects with Advanced Non-Small Cell Lung Cancer
    LEAD INVESTIGATOR: Prof Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here

There are currently no trials actively recruiting to this stream. Please refer to “Solid Tumours and Phase 1 Studies” for trials including multiple cancer types.

  • TRIAL REFERENCE:  LH16.052 SHR3680
    SUMMARY: A phase I trial of SHR3680 in subjects with metastatic castration-resistant prostate cancer as monotherapy
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.062 GALAHAD
    SUMMARY: Clinical Study No. 64091742PCR2001 : A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.044 GSK204697/PXL230779
    SUMMARY: Clinical Study No. 204697 – a phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprevation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC)
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.011 CA209-9KD
    SUMMARY: A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD:CHECKpoint pathway and nivoluMAb clinical Trials Evaluation 9KD)
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.031 LEEP
    SUMMARY: A Randomised controlled Phase II trial of the pharmacodynamic effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.003 JPCM_Prostate
    SUMMARY: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of  Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostrate Cancer
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.005  AMG 160
    SUMMARY: A Phase 1 Study evaluating the Safety ,Tolerability, Pharmacokinteics and Efficacy of Prostate Specific Membrane Antigen Half-Lie Extended Bispecific T-cell Engager AMG 160 in subjects with metastatic Castration-resistant Prostate Canver
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.022 C3441021
    SUMMARY: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Background Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With DNA Damage Repair Deficiencies
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.055 UNISoN ANZUP 1602
    SUMMARY: A Phase II Sequential Treatment Trial of single Agent Nivolumab, the Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Renal cell Carcinoma (ANZUP1602)
    LEAD INVESTIGATOR: Michelle Harrison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.030 CX839-008 (Calithera/CANTATA)
    SUMMARY: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) – CANTATA
    LEAD INVESTIGATOR: Dr Michelle Harrison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.033 RENO 26 JX594
    SUMMARY: Clinical Study No. JX594-REN026. A Phase 1b Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactived Vaccinia Virus plus GM-CSF) in Combination with REGN2810 (anti PD-1) in Patients with Metastatic or Unresectable Renal Cell Carcinoma (RCC)
    LEAD INVESTIGATOR: Dr Michelle Harrison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.045 CA209-933ISR
    SUMMARY: Nivolumab in renal transplant recipients with poor prognosis cancers – a safety study.
    LEAD INVESTIGATOR: Prof Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.038 EZH-202
    SUMMARY: Clinical Study No. EZH-202, A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
    LEAD INVESTIGATOR: David Thomas
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.023 SU2C-SARC-032
    SUMMARY: SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
    LEAD INVESTIGATOR: A/Prof Angela Hong
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.007  NORTH
    SUMMARY: A Phase III Study of Panobinostat in Paediatric, Adolescent and Young Adult patients with Solid Tumors including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma
    LEAD INVESTIGATOR: Dr Vivek Bhadri
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.019 rECCUr
    SUMMARY: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
    LEAD INVESTIGATOR: Dr Vivek Bhadri
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.005 MK-3475-158
    SUMMARY: Clinical Study No. MK-3475-158 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
    LEAD INVESTIGATOR: Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.030 D6070C00001
    SUMMARY: A Phase 1 Multicenter, Open-Label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors
    LEAD INVESTIGATOR: Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.052 SHR3680
    SUMMARY: A phase I trial of SHR3680 in subjects with metastatic castration-resistant prostate cancer as monotherapy
    LEAD INVESTIGATOR: Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.025 GSK2017973/PXL230774
    SUMMARY: A Phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK522762 in combination with fulvestrant in submects with ER+ breast cancer
    LEAD INVESTIGATOR: Catriona McNeil
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.040 MGA 012
    SUMMARY: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors
    LEAD INVESTIGATOR: Vivek Bhadri
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.044 GSK204697/PXL230779
    SUMMARY: A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprevation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC)
    LEAD INVESTIGATOR: Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.050 APG 1252
    SUMMARY: A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) or Other Solid Tumors
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.053 MK7684-001
    SUMMARY: A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumours
    LEAD INVESTIGATOR: Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.058 AMG 757
    SUMMARY: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer’ 20160323
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.002 BGB-290-103
    SUMMARY: A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.020 B9991023
    SUMMARY: A Multicentre open labe; Phase 1B/2 study to evaluate safety & efficacy of Avelumab (MSB0010718C) in combination with Chemotherapy with or without other anti-cancer immunotherapies as first line treatment in patients with advanced malignancies
    LEAD INVESTIGATOR: Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.021 TIGER TICE
    SUMMARY: A randomised Phase III trial comparing conventional dose chemotherapy using paclitaxel, ifosfamide & cisplatin (TIP) with high dose chemptherapy using mobilising paclitaxel plus ifosfamide followed by high dose carboplatin & etoposide (TI-CE) as first salvage treatment in relapsed or refactory germ cell tumors
    LEAD INVESTIGATOR: Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.026 CP-MGD009-01
    SUMMARY: Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.042 AB928-CSP0003
    SUMMARY: A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies.
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.043 AB928-CSP0002
    SUMMARY: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies.
    LEAD INVESTIGATOR: Dr Chen Lee
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.004 FPT155-001
    SUMMARY: A Phase 1a/1b Study of FPT155 in patients with advanced Solid Tumors
    LEAD INVESTIGATOR: Dr Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.008 MK3475-587
    SUMMARY: A Multi-center, Open label, Phase III Extension Trial to Study the Long-term   Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
    LEAD INVESTIGATOR: Dr Catriona McNeil
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.024 AMG 404
    SUMMARY: A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients with Advanced Solid Tumors’
    LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.020 AB154CSP0001
    SUMMARY: A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
    LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.040 THOR – JNJ 42756493
    SUMMARY: Clinical Study JNJ42756493 : a Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene
    LEAD INVESTIGATOR: Professor Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search